FDA Approves Controversial Alzheimer’s Drug


Sumary of FDA Approves Controversial Alzheimer’s Drug:

  • June 07, 2021 — Amid significant controversy, the FDA on Monday approved the drug aducanumab for the treatment of Alzheimer’s disease (AD), ignoring the recommendation by its own advisory panel to reject the drug..
  • Aducanumab was fast-tracked for approval, a process reserved for drugs that provide a meaningful advantage over existing treatments for a serious or life-threatening illness..
  • In a release, the FDA agency said if the drug fails to show clinical benefit in this trial it has the option to withdraw its approval..
  • Aducanumab’s approval marks the first new treatment approved for Alzheimer since 2003 and is the first to target beta-amyloid, the hallmark pathology of the disease..
  • pic.twitter.com/2oJIeMADog In November, the Peripheral and Central Nervous System Drugs Advisory Committee voted 8 to 1 against approving the drug because, based on clinical trial results, evidence of efficacy was not strong enough..
  • The FDA noted that today’s approval was based on three separate double-blind, randomized studies representing 3,382 Alzheimer patients..
  • Rocky Road The road to approval has been extremely rocky for aducanumab, an anti-amyloid-beta human monoclonal antibody, previously known as BIIB037..
  • However, 1 year later, a majority of the members of the FDA’s advisory panel were against the drug’s approval….

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.